LYEL
Lyell Immunopharma, Inc.Lyell Immunopharma, Inc. reported revenue of $36.0K in its most recent fiscal year, down 41.0% on the year before. It kept -762355.6% of that as net income, and generated -$150.80M of free cash flow. Figures below are compared against other companies classified under Pharmaceutical Preparations.
Grades vs. industry
Growth
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Revenue growth (YoY) Latest fiscal year revenue vs. the year before. | -41.0% | 7.4% | 173 / 219 |
Revenue growth (3y) Annualized revenue growth over three fiscal years. | -92.5% | 7.6% | 186 / 186 |
Revenue growth (5y) Annualized revenue growth over five fiscal years. | -65.9% | 7.3% | 169 / 169 |
EPS growth (YoY) Diluted EPS vs. the prior fiscal year. | Not reported | -33.3% | — |
EPS growth (3y) Annualized diluted EPS growth over three fiscal years. | Not reported | 4.0% | — |
EPS growth (5y) Annualized diluted EPS growth over five fiscal years. | Not reported | 3.8% | — |
Free cash flow growth (YoY) Operating cash flow less capital expenditure, vs. prior year. | Not reported | -7.9% | — |
Free cash flow growth (3y) Annualized free cash flow growth over three fiscal years. | Not reported | 1.4% | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | Not reported | 72.1% | — |
Operating margin Operating income as a share of revenue. | -748344.4% | -34.2% | — |
Net margin Net income as a share of revenue. | -762355.6% | -30.0% | — |
Free cash flow margin Free cash flow as a share of revenue. | -418900.0% | -15.3% | — |
Return on equity Net income divided by shareholder equity. | -110.6% | -52.3% | 265 / 368 |
Return on assets Net income divided by total assets. | -80.7% | -37.6% | 309 / 419 |
Return on invested capital After-tax operating profit over debt plus equity less cash. | -113.2% | -49.3% | 195 / 257 |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | Not reported | 0.24x | — |
Current ratio Current assets over current liabilities. | 5.28x | 4.17x | 169 / 419 |
Quick ratio Current assets excluding inventory, over current liabilities. | 5.28x | 3.84x | 169 / 419 |
Interest coverage Operating income divided by interest expense. | Not reported | -15.21x | — |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | Not reported | -1.56x | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Insider activity
Trades reported by officers, directors and 10% shareholders on SEC Form 4. None of the last 12 reported transactions were open-market purchases — grants, option exercises and sales make up the majority of insider filings at most companies.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 12, 2026 | Aguirre Jarrad Mattieu Chief Medical Officer | Open-market sale | 422 | $8.63 | $3.6K |
| Sep 10, 2026 | Shook David Chief Medical Officer | Open-market sale | 500 | $12.70 | $6.3K |
| Sep 10, 2026 | Aguirre Jarrad Mattieu Chief Medical Officer | Grant or award(derivative) | 47,500 | $0.00 | $0.00 |
| Aug 21, 2026 | Seely Lynn President and CEO | Open-market sale | 9,589 | $15.54 | $149.0K |
| Aug 21, 2026 | Lee Gary K. Chief Scientific Officer | Open-market sale | 1,457 | $15.54 | $22.6K |
| Aug 21, 2026 | Hill Stephen J. Chief Operating Officer | Open-market sale | 989 | $15.54 | $15.4K |
| Aug 10, 2026 | Bulis Veronica Sanchez VP, Corporate Controller | Open-market sale | 621 | $14.34 | $8.9K |
| Aug 10, 2026 | Seely Lynn President and CEO | Open-market sale | 390 | $14.34 | $5.6K |
| Aug 10, 2026 | Lee Gary K. Chief Scientific Officer | Open-market sale | 131 | $14.34 | $1.9K |
| Aug 10, 2026 | Hill Stephen J. Chief Operating Officer | Open-market sale | 89 | $14.34 | $1.3K |
| Jul 27, 2026 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Other | 38,500 | $0.00 | $0.00 |
| Jul 27, 2026 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Other | 44,000 | $0.00 | $0.00 |
A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.
Annual financials
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $36.0K | $61.0K | $130.0K | $84.68M | $10.65M | $7.76M | $657.0K |
| Operating income | -$269.40M | -$358.75M | -$247.01M | -$187.06M | -$214.78M | -$211.94M | -$102.09M |
| Net income | -$274.45M | -$342.99M | -$234.63M | -$183.12M | -$250.22M | -$204.47M | -$129.38M |
| EPS (diluted) | -$16.06 | -$26.23 | -$18.70 | n/c | n/c | n/c | n/c |
| Operating cash flow | -$150.02M | -$162.39M | -$163.69M | -$169.56M | -$126.25M | -$160.87M | $39.47M |
| Capital expenditure | $780.0K | $464.0K | $2.69M | $24.28M | $65.50M | $51.48M | $16.05M |
| Free cash flow | -$150.80M | -$162.86M | -$166.38M | -$193.83M | -$191.75M | -$212.35M | $23.43M |
| Total assets | $340.05M | $490.86M | $750.03M | $937.56M | $1.13B | $908.28M | — |
| Shareholder equity | $248.20M | $382.82M | $654.95M | $833.25M | $929.79M | -$292.53M | -$111.11M |
| Cash | $60.18M | $105.60M | $145.65M | $123.55M | $293.83M | $140.41M | $96.67M |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
n/c marks per-share figures that are not comparable. Companies report each year as their filings stated it, and an annual report restates only its two prior years — so after a stock split, older years remain on the pre-split share count. Totals above are unaffected.
Source
Figures come from Lyell Immunopharma, Inc.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K filed Mar 12, 2026. View filings on EDGAR.